Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database
This study highlights significant variability in the proportion of T2D subjects meeting SGLT2i CVOT inclusion criteria, with DECLARE-TIMI-58 being the most represented. Low SGLT2i prescription rates in the Italian primary care setting, along with substantial demographic and clinical differences between SGLT-2i users and T2D eligible patients, emphasize the need for targeted interventions to optimize the use of these medications in primary care settings.
Authors
- Claire B. Paris (ORCID: https://orcid.org/0000-0002-0637-1334)
- Anna Rita Maurizi
- Davide Rozza (ORCID: https://orcid.org/0000-0003-2648-742X)
- Marco Gnesi (ORCID: https://orcid.org/0000-0001-6022-6325)
- Caroline Eteve‐Pitsaer
- Silvia Mele (ORCID: https://orcid.org/0000-0003-3709-5739)
- Carla Fornari (ORCID: https://orcid.org/0000-0002-9609-9556)
- LG Mantovani (ORCID: https://orcid.org/0000-0003-3866-8199)
- Pasquale Palladino (ORCID: https://orcid.org/0000-0002-3869-5085)
- Marco D’Amelio (ORCID: https://orcid.org/0000-0002-2178-6749)
- Ippazio Cosimo Antonazzo (ORCID: https://orcid.org/0000-0001-8046-4574)
- E Ferrari (ORCID: https://orcid.org/0009-0009-0958-7825)
- P. Cortesi (ORCID: https://orcid.org/0000-0002-2992-4253)
- Giampiero Mazzaglia
Institutions
- University of Pisa (IT)
- Cegedim (France) (FR)
- IRCCS Istituto Auxologico Italiano (IT)
- AstraZeneca (Italy) (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Data Management (Italy) (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Acta Diabetologica
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s00592-024-02359-1
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- AstraZeneca
- Università degli Studi di Milano
- Università degli Studi di Milano-Bicocca